Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals (RYTM) reported Q2 2026 revenue of $71.3M, up 19% sequentially. U.S. revenue was $51M, up 38% sequentially, while international sales fell to $20.3M due to a $3.8M French retrospective charge. Management said cash and short-term investments were $330.9M, guiding FY26 non-GAAP OpEx to $363M-$397M and R&D to $175M-$195M.
How this was made
The 30-second read
Why it matters
Key new items for traders are the reported Q2 revenue and sequential growth, FY2026 expense and R&D guidance adjustments, and RM-718 Phase II outcomes (BMI reduction and absence of generalized hyperpigmentation). International commentary adds a France charge headwind and a Japan launch window for Q4 2026.
Market read
This is a company-specific earnings and clinical update with multiple fresh quantitative disclosures that can drive near-term expectation changes for launch trajectory and pipeline de-risking.
What to watch
Gross-to-net yield of 86% and the $2.9M inventory revenue benefit suggest revenue quality and timing effects; adoption speed in busy endo offices may slow near-term patient identification.
Background
The transcript covers Rhythm Pharmaceuticals Q2 2026 results and business update, including U.S. launch progress for IMCIVREE and Phase II data for RM-718 in acquired hypothalamic obesity.
Ticker impact
Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M, guided FY2026 non-GAAP OpEx $363M-$397M, and updated RM-718 Phase II efficacy and safety.
Moderately positive bias for near-term trading as guidance and Phase II safety/efficacy support the HO commercialization and RM-718 de-risking narrative.
The article includes multiple new, decision-relevant figures (revenue, sequential growth, FY expense guidance, R&D midpoint reduction, and RM-718 Phase II outcomes) that can move expectations for launch execution and pipeline value.
Market effects
Reinforces demand and payer activation momentum for rare obesity therapies and highlights manufacturing-timeline driven R&D guidance changes.
International weakness in France is attributed to regulatory charges, while Japan launch timing is flagged for Q4 2026.
Supports broader investor sentiment toward GLP-1-adjacent and hypothalamic obesity franchises, with Europe reimbursement uncertainty remaining a key overhang.
Counterpoint
Despite positive RM-718 safety/efficacy and U.S. growth, the France regulatory charge and the R&D guidance reduction signal execution and cost/timing risks that could cap upside.
Key entities
- companyRhythm Pharmaceuticals
Subject of the earnings call transcript, providing Q2 2026 financial results, FY2026 guidance, and RM-718 Phase II updates.
- productIMCIVREE
Commercial therapy referenced as having launched in the U.S. after March 19, 2026 approval for acquired hypothalamic obesity.
- clinical_programRM-718
Phase II program in acquired hypothalamic obesity with reported BMI reduction and safety observations.
